← Back to Holdings
VR Adviser, LLC
CIK 1615982 · 2024-Q4 · 2 filing(s) · prev: 2024-Q3
Total Portfolio Value
$1.5T
Positions
37
4 exited vs prev quarter
Latest Filing
2024-Q4
Due Diligence Score
Institutional quality assessment based on 13F data
F
24 / 100
Filing Longevity3/30
2 quarters of history
Portfolio Breadth1/25
37 positions
Equity Purity20/20
0 options positions (0.0%)
Concentration Balance0/25
Top-5 = 50.4% of portfolio
Loading timeline…
AI Portfolio Analysis
Claude-powered institutional analyst commentary
Portfolio Profile
Relative positioning across key dimensions (0–100)
Top Holdings by Value
Top 30 positions by value
| # | Issuer | Class | CUSIP | Value | Shares | % Portfolio | Type |
|---|---|---|---|---|---|---|---|
| 1 | ▼APOGEE THERAPEUTICS INC | COM | 03770N101 | $384.7B | 8,493,321 | 26.40% | EQ |
| 2 | ▼OCULAR THERAPEUTIX INC | COM | 67576A100 | $109.0B | 12,762,462 | 7.48% | EQ |
| 3 | ▼ENLIVEN THERAPEUTICS INC | COM | 29337E102 | $90.6B | 4,026,331 | 6.22% | EQ |
| 4 | ▲PRAXIS PRECISION MEDICINES I | COM NEW | 74006W207 | $76.2B | 989,985 | 5.23% | EQ |
| 5 | ▼VIRIDIAN THERAPEUTICS INC | COM | 92790C104 | $74.4B | 3,882,709 | 5.11% | EQ |
| 6 | ▼ORUKA THERAPEUTICS INC | COM | 687604108 | $63.7B | 3,285,620 | 4.37% | EQ |
| 7 | ▼SPYRE THERAPEUTICS INC | COM NEW | 00773J202 | $62.5B | 2,685,448 | 4.29% | EQ |
| 8 | ▼PHARVARIS N V | COM | N69605108 | $61.7B | 3,220,130 | 4.24% | EQ |
| 9 | ▼KALVISTA PHARMACEUTICALS INC | COM | 483497103 | $52.9B | 6,249,731 | 3.63% | EQ |
| 10 | ▼DYNE THERAPEUTICS INC | COM | 26818M108 | $51.2B | 2,173,913 | 3.51% | EQ |
| 11 | ▼COGENT BIOSCIENCES INC | COM | 19240Q201 | $44.3B | 5,684,411 | 3.04% | EQ |
| 12 | ▼ERASCA INC | COM | 29479A108 | $40.7B | 16,216,216 | 2.79% | EQ |
| 13 | ▼DIANTHUS THERAPEUTICS INC | COM | 252828108 | $38.0B | 1,744,373 | 2.61% | EQ |
| 14 | NEWUPSTREAM BIO INC | COM | 91678A107 | $37.7B | 2,295,319 | 2.59% | EQ |
| 15 | ▼ORIC PHARMACEUTICALS INC | COM | 68622P109 | $35.5B | 4,394,527 | 2.43% | EQ |
| 16 | ▲ENGENE HOLDINGS INC | COM | 29286M105 | $33.6B | 5,046,414 | 2.30% | EQ |
| 17 | ▼MERUS N V | COM | N5749R100 | $24.9B | 592,411 | 1.71% | EQ |
| 18 | ▼ASTRIA THERAPEUTICS INC | COM | 04635X102 | $22.0B | 2,457,348 | 1.51% | EQ |
| 19 | NEWCIDARA THERAPEUTICS INC | COM NEW | 171757206 | $20.6B | 765,723 | 1.41% | EQ |
| 20 | ▼CULLINAN THERAPEUTICS INC | COM | 230031106 | $16.8B | 1,379,965 | 1.15% | EQ |
| 21 | ▼4D MOLECULAR THERAPEUTICS IN | COM | 35104E100 | $16.4B | 2,952,371 | 1.13% | EQ |
| 22 | ▼ARTIVA BIOTHERAPEUTICS INC | COM | 04317A107 | $16.2B | 1,609,569 | 1.11% | EQ |
| 23 | ▼MERSANA THERAPEUTICS INC | COM | 59045L106 | $14.7B | 10,257,790 | 1.01% | EQ |
| 24 | ▼ABIVAX SA | SPONSORED ADS | 00370M103 | $9.9B | 1,345,780 | 0.68% | EQ |
| 25 | ▼AQUESTIVE THERAPEUTICS INC | COM | 03843E104 | $9.4B | 2,629,786 | 0.64% | EQ |
| 26 | ▼APPLIED THERAPEUTICS INC | COM | 03828A101 | $8.6B | 9,990,591 | 0.59% | EQ |
| 27 | ▲PERCEPTIVE CAP SOLUTIONS COR | CL A ORD SHS | G70077105 | $7.6B | 750,000 | 0.52% | EQ |
| 28 | ▼TERNS PHARMACEUTICALS INC | COM | 880881107 | $6.0B | 1,077,090 | 0.41% | EQ |
| 29 | ▼TAYSHA GENE THERAPIES INC | COM SHS | 877619106 | $5.6B | 3,225,180 | 0.38% | EQ |
| 30 | ▼TREVI THERAPEUTICS INC | COM | 89532M101 | $5.2B | 1,266,457 | 0.36% | EQ |
| 31 | ▼ZURA BIO LTD | CLASS A ORD SHS | G9TY5A101 | $5.1B | 2,023,166 | 0.35% | EQ |
| 32 | ▼CENTURY THERAPEUTICS INC | COM | 15673T100 | $4.0B | 3,957,186 | 0.27% | EQ |
| 33 | ▼CASI PHARMACEUTICALS INC | ORD SHS | G1933S101 | $2.8B | 987,259 | 0.19% | EQ |
| 34 | ▼TENAYA THERAPEUTICS INC | COM | 87990A106 | $2.2B | 1,555,556 | 0.15% | EQ |
| 35 | ▲TENAX THERAPEUTICS INC | COM NEW | 88032L605 | $1.3B | 208,333 | 0.09% | EQ |
| 36 | NEWGLYCOMIMETICS INC | COM | 38000Q102 | $747.0M | 3,000,000 | 0.05% | EQ |
| 37 | ▼INSTIL BIO INC | COM NEW | 45783C200 | $633.3M | 33,177 | 0.04% | EQ |